Regulation of proteasome complexes by gamma-interferon and phosphorylation.
Proteasomes play a major role in non-lysosomal proteolysis and also in the processing of proteins for presentation by the MHC class I pathway. In animal cells they exist in several distinct molecular forms which contribute to the different functions. 26S proteasomes contain the core 20S proteasome together with two 19S regulatory complexes. Alternatively, PA28 complexes can bind to the ends of the 20S proteasome to form PA28-proteasome complexes and PA28-proteasome-19S hybrid complexes have also been described. Immunoproteasome subunits occur in 26S proteasomes as well as in PA28-proteasome complexes. We have found differences in the subcellular distribution of the different forms of proteasomes. The gamma-interferon inducible PA28 alpha and beta subunits are predominantly located in the cytoplasm, while 19S regulatory complexes (present at significant levels only in 26S complexes) are present in the nucleus as well as in the cytoplasm. Immunoproteasomes are greatly enriched at the endoplasmic reticulum (ER) where they may facilitate the generation of peptides for transport into the lumen of the ER. We have also investigated the effects of gamma-interferon on the levels and subcellular distribution of inducible subunits and regulator subunits. In each case gamma-interferon was found to increase the level but not to alter the distribution. Several subunits of proteasomes are phosphorylated including alpha subunits C8 (alpha7) and C9 (alpha3), and ATPase subunit S4 (rpt2). Our studies have shown that gamma-interferon treatment decreases the level of phosphorylation of proteasomes. We have investigated the role of phosphorylation of C8 by casein kinase II by site directed mutagenesis. The results demonstrate that phosphorylation at either one of the two sites is essential for the association of 19S regulatory complexes and that the ability to undergo phosphorylation at both sites gives the most efficient incorporation of C8 into the 26S proteasome.
Rivett
A J
AJ
Department of Biochemistry, University of Bristol, School of Medical Sciences, BS8 1TD, Bristol, UK. j.rivett@bristol.ac.uk
Bose
S
S
Brooks
P
P
Broadfoot
K I
KI
D000818:Animals; D002467:Cell Nucleus / Q000201:enzymology; D003546:Cysteine Endopeptidases / Q000187:drug effects / Q000378:metabolism*; D003593:Cytoplasm / Q000201:enzymology; D004721:Endoplasmic Reticulum / Q000201:enzymology; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism* / Q000494:pharmacology; D008322:Mammals / Q000378:metabolism; D009097:Multienzyme Complexes / Q000187:drug effects / Q000378:metabolism*; D009124:Muscle Proteins; D010447:Peptide Hydrolases / Q000187:drug effects / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D046988:Proteasome Endopeptidase Complex; D021122:Protein Subunits; D011506:Proteins / Q000187:drug effects / Q000378:metabolism*; D015003:Yeasts / Q000378:metabolism
D009097:Multienzyme Complexes; D009124:Muscle Proteins; C085047:PSME1 protein, human; D021122:Protein Subunits; D011506:Proteins; C071313:LMP-2 protein; D007371:Interferon-gamma; D010447:Peptide Hydrolases; D003546:Cysteine Endopeptidases; C098949:proteasome subunit Z; C077436:LMP7 protein; C098948:PSMB10 protein, human; D046988:Proteasome Endopeptidase Complex; C061553:ATP dependent 26S protease